WO2005118521A1 - Monomethylphytosphingosine et composition anticancereuse contenant ce compose - Google Patents

Monomethylphytosphingosine et composition anticancereuse contenant ce compose Download PDF

Info

Publication number
WO2005118521A1
WO2005118521A1 PCT/KR2005/001436 KR2005001436W WO2005118521A1 WO 2005118521 A1 WO2005118521 A1 WO 2005118521A1 KR 2005001436 W KR2005001436 W KR 2005001436W WO 2005118521 A1 WO2005118521 A1 WO 2005118521A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
monomethylphytosphingosine
mmps
composition
sphingosine
Prior art date
Application number
PCT/KR2005/001436
Other languages
English (en)
Inventor
Dae-Seog Lim
Jinwook Kim
Sungjin Park
You-A Hwang
Changseo Park
Ho-Jae Lee
Original Assignee
Doosan Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Doosan Corporation filed Critical Doosan Corporation
Publication of WO2005118521A1 publication Critical patent/WO2005118521A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine

Definitions

  • PPMP D-1hreo-l-phenyl-2-palrnitoylamino-3-mo ⁇ holino-l-propanol
  • PPPP P4D-1hreo-l-phenyl-2-palrnitoylamino-3-pyrrolidino-l-propanol
  • the P-drug is expected to exhibit an anti-cancer effect for a general cancer cell and to inhibit a synthesis of GlcCer relating to tolerance to the anti-cancer drug, thereby contributing to a prevention of drug resistance.
  • B13 or N-oleoylethanolamine which are ceramidase inhibitors, is also a ceramide analog and inhibits a decomposition of the ceramide to induce a death of the cancer cell.
  • ceramide biosynthesis inhibitors having a structure similar to those of sphingoiipid and ceramide, such as FTY-720, fumonisin and myriosin, etc.
  • composition for inhibiting sphingosine kinase containing the monomethylphytosphingosine (MMPS) or a pharmaceutically acceptable salt thereof as an effective ingredient a composition for inhibiting sphingosine kinase containing the monomethylphytosphingosine (MMPS) or a pharmaceutically acceptable salt thereof as an effective ingredient.
  • MMPS monomethylphytosphingosine
  • FIG. 1 is a graph showing cytotoxicity of MMPS for MDA-MB-231 cells.
  • CHO-K1 Choinese Hamster Ovary: ATCC Number: CCL-61, which is a cell line transfected with sphingosine kinase genes
  • substrate 10-40 mM
  • MMPS 10-100 mM
  • ATP 0.5 mM, Hot 2uCi ml
  • a proper amount of hydrochloric acid was added to be a solution.
  • a proper amount of sodium hydroxide was added to be pH 6.0.
  • a proper amount of purified water was added to be 100 mg.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une monométhylphytosphingosine (MMPS) ou un de ses sels de qualité pharmaceutique, ainsi qu'une composition contenant ce composé ou ce sel. Ce composé permet d'inhiber efficacement une activité de la sphingosine kinase et, ainsi, de bloquer de nombreux mécanismes induits par la sphingosine kinase. L'invention permet plus particulièrement d'éviter qu'un céramide et qu'une sphingosine soient phosphorylés en raison de la sphingosine kinase, de maintenir les concentrations de céramide et de sphingosine élevées et, par conséquent, d'induire l'apoptose d'une cellule cancéreuse et de traiter un cancer ou de prévenir l'apparition d'une maladie liée à un cancer. De plus, du fait que l'invention permet d'inhiber une activité induisant une prolifération cellulaire de la sphingosine kinase, elle peut être utilisée pour le traitement ou la prévention d'une maladie hyperproliférante, tel que le cancer ou le psoriasis.
PCT/KR2005/001436 2004-06-01 2005-05-17 Monomethylphytosphingosine et composition anticancereuse contenant ce compose WO2005118521A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020040039703A KR100705054B1 (ko) 2004-06-01 2004-06-01 모노메틸파이토스핑고신 및 그를 함유하는 항암 조성물
KR10-2004-0039703 2004-06-01

Publications (1)

Publication Number Publication Date
WO2005118521A1 true WO2005118521A1 (fr) 2005-12-15

Family

ID=35462862

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2005/001436 WO2005118521A1 (fr) 2004-06-01 2005-05-17 Monomethylphytosphingosine et composition anticancereuse contenant ce compose

Country Status (2)

Country Link
KR (1) KR100705054B1 (fr)
WO (1) WO2005118521A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166094A1 (fr) 2008-09-23 2010-03-24 Ecole Normale Superieure De Lyon Procédés pour le prolongement des avantages sanitaires déclenchés par une restriction alimentaire utilisant un inhibiteur de la sphingosine kinase

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100823146B1 (ko) * 2006-12-28 2008-04-22 재단법인 한국원자력의학원 신규 파이토스핑고신 유도체 및 이를 이용한 방사선치료증진제

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583160A (en) * 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
WO2003092667A1 (fr) * 2002-05-02 2003-11-13 Doosan Corporation Composition permettant de traiter le cancer comprenant n,n-dimethylphytosphingosine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02215711A (ja) * 1989-02-03 1990-08-28 Biomembrane Inst プロテインキナーゼ阻害剤としての、ｎ‐メチル‐スフィンゴシン誘導体及びその立体異性体
GB9308103D0 (en) 1993-04-20 1993-06-02 Unilever Plc Cosmetic composition
US6098631A (en) 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583160A (en) * 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
WO2003092667A1 (fr) * 2002-05-02 2003-11-13 Doosan Corporation Composition permettant de traiter le cancer comprenant n,n-dimethylphytosphingosine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIRT D.F. ET AL: "Inhibition of skin carcinomas but not papillomas by sphingosine,N-methylsphingosine, and N-acetylsphingosine", NUTRITION AND CANCER, vol. 31, no. 2, 1998, pages 119 - 126, XP008008431 *
NATZKER ET AL: "cis-4-methylsphingosine phosphate induces apoptosis in neuroblastoma cells by opposite effects on p38 and ERK mitogen-activated protein kinases", BIOLOGICAL CHEMISTRY, vol. 383, no. 12, 2002, pages 1885 - 1894 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166094A1 (fr) 2008-09-23 2010-03-24 Ecole Normale Superieure De Lyon Procédés pour le prolongement des avantages sanitaires déclenchés par une restriction alimentaire utilisant un inhibiteur de la sphingosine kinase

Also Published As

Publication number Publication date
KR100705054B1 (ko) 2007-04-06
KR20050114477A (ko) 2005-12-06

Similar Documents

Publication Publication Date Title
EP2892518B1 (fr) Nouvelles approches thérapeutiques pour le traitement de la maladie de parkinson
KR102014883B1 (ko) 근위축성 측삭 경화증 치료용 신규 조성물
US20140179779A1 (en) Deuterium Substituted Fumarate Derivatives
CN103845317B (zh) 恩他卡朋在预防或治疗肥胖等代谢综合征中的应用
KR20090082213A (ko) 페닐알킬아미노 카바메이트 조성물
CN101969954A (zh) 三芳基甲烷类似物及其在治疗癌症中的用途
CN103561729A (zh) 紫檀茋的抗焦虑效果
CN101820848A (zh) 抑制n-酰基乙醇胺水解性酸酰胺酶的组合物和方法
KR20120101473A (ko) 아라키돈산 유사체 및 이를 사용한 진통제 치료 방법
KR20090067210A (ko) 페닐알킬 카바메이트 조성물
US11897875B2 (en) Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type a receptors as fast acting treatment for depression and mood disorders
WO2008000142A1 (fr) Agoniste du transporteur de la dopamine et ses utilisations
CS208660B2 (en) Method of making the n-/2-phenyl-2-hydroxyethyl/-1,1-dimethyl-3-phenylpropylamin derivatives
PT2506842E (pt) Formulações, sais e polimorfos de transnorsertralina e suas utilizações
BRPI0707557A2 (pt) neurogÊnese medida por derivado de 4-acilaminopiridina
JP2007510737A (ja) 癌処置のためのセラミド異化阻害剤としてのｐｐｍｐ
WO2006004359A1 (fr) Derives de sphingolipides et composition anticancereuse contenant lesdits derives
WO2005118521A1 (fr) Monomethylphytosphingosine et composition anticancereuse contenant ce compose
Kim et al. Structure–activity relationship of salicylic acid derivatives on inhibition of TNF-α dependent NFκB activity: Implication on anti-inflammatory effect of N-(5-chlorosalicyloyl) phenethylamine against experimental colitis
CN103826622B (zh) 用于预防或治疗情感障碍的n-取代的苯丙酰胺或苯丙烯酰胺
CA2482784A1 (fr) Composition permettant de traiter le cancer comprenant n,n-dimethylphytosphingosine
AU2021202066A1 (en) Use of iminosugar compound in preparation of anti-sars-cov-2 virus drug
CN114504579A (zh) 一种预防、治疗疼痛、炎症的化合物及其应用
US20220409577A1 (en) Intratumoral administration of ascorbic acid and quinone compounds for tumor treatment
WO2005118522A1 (fr) Monomethylphytosphingosine- polyethylenegly col et composition anti-cancereuse contenant ledit compose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase